Dianthus Therapeutics, Inc. /DE/ (DNTH) Institutional Ownership

Ownership Summary

A total of 142 institutions have reported a stake in Dianthus Therapeutics, Inc. /DE/ (NASDAQ:DNTH) as of September 2025, according to recent 13F filings with the SEC.

• Dianthus Therapeutics saw its institutional ownership percentage rose to 146.8% in September 2025 from 119.8% in June 2025.
• The company experienced a 24.56% quarterly change in institutional shares held, alongside an increase of 57.78% in total owners annually.
• Among the 142 institutional holders of Dianthus Therapeutics, 90 added to their stakes while 41 trimmed their positions and 11 held steady.
• This class of investors increased its holdings in Dianthus Therapeutics to 47.24Mn shares for the 13F-cycle ending September 2025, up by 9.32Mn shares quarter on quarter, and up 15.89Mn shares year over year.
• With 5.97Mn shares, FMR LLC commands the largest institutional position in Dianthus Therapeutics as of September 30, 2025, equating to 18.55% of the company.
• Among the most significant buyers of Dianthus Therapeutics during September 2025 were WELLINGTON MANAGEMENT GROUP LLP (2.50Mn), Avidity Partners Management LP (1.46Mn), FMR LLC (1.43Mn), Polar Capital Holdings Plc (748.00K), Point72 Asset Management, L.P. (649.44K).
• Leading sellers of Dianthus Therapeutics stock in September 2025 included Vestal Point Capital, LP (2.02Mn), Bain Capital Life Sciences Investors, LLC (1.17Mn), 5AM Venture Management, LLC (619.67K), Woodline Partners LP (357.81K), ALLIANCEBERNSTEIN L.P. (322.44K).
• The top 10 institutional holders of Dianthus Therapeutics for the quarter ending September 2025 included FMR LLC (5.97Mn), Fairmount Funds Management LLC (3.31Mn), Avidity Partners Management LP (3.20Mn), RA CAPITAL MANAGEMENT, L.P. (2.87Mn), WELLINGTON MANAGEMENT GROUP LLP (2.58Mn), Octagon Capital Advisors LP (2.42Mn), Point72 Asset Management, L.P. (2.04Mn), TCG Crossover Management, LLC (1.68Mn), VANGUARD GROUP INC (1.64Mn), BlackRock, Inc. (1.34Mn).